Targeting p38 gamma signaling to advance Cutaneous T Cell Lymphoma Therapy
靶向 p38 γ 信号传导以推进皮肤 T 细胞淋巴瘤治疗
基本信息
- 批准号:10296667
- 负责人:
- 金额:$ 67.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-12-01 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAnimal ModelBindingBiologicalCRISPR screenCell DeathCell LineChemicalsClinicalComputer ModelsComputing MethodologiesCutaneous T-cell lymphomaDataDevelopmentDrug resistanceElementsFDA approvedFutureGene ExpressionGene SilencingGoalsGrowthHistone DeacetylaseHistone Deacetylase InhibitorIn VitroLeadLearningLigandsLymphomaLymphoma cellMalignant - descriptorMalignant NeoplasmsMediatingMethodologyMitogen-Activated Protein KinasesMolecularOrganic SynthesisOutcomePathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhosphorylationPhosphotransferasesPlayPositioning AttributePrognosisProteinsRNA interference screenReceptor SignalingRegimenResearchResearch PersonnelRoleSamplingSignal PathwaySignal TransductionSignal Transduction PathwaySignaling ProteinSiteStructureT-Cell LymphomaT-Cell ReceptorT-LymphocyteTestingTherapeuticTherapeutic EffectTreatment outcomeValidationVorinostatWorkXenograft procedureadvanced diseaseanalogbasecancer cellcell killingchemical geneticsclinical applicationclinically relevantclinically significantcytotoxiccytotoxicitydrug discoveryexperiencegenetic approachhigh throughput screeningimprovedimproved outcomein vivoinhibitorinnovationknock-downmolecular modelingmouse modelnanomolarnew therapeutic targetnovelnovel therapeuticsp38 Mitogen Activated Protein Kinasepatient derived xenograft modelpatient prognosisprotein protein interactionresponsescaffoldscreeningsmall moleculesmall molecule inhibitortargeted treatmenttherapeutically effectivetumorigenesis
项目摘要
Cutaneous T cell lymphoma (CTCL) is a disfiguring, incurable cancer. For patients with advanced disease,
current therapies are inadequate, and outcome is poor. An incomplete understanding of CTCL molecular
regulators has limited development of effective targeted therapies. One candidate regulator is p38γ, the gene
expression of which is selectively increased in CTCL cell lines and patient samples, but not healthy T cells. We
demonstrate that inhibition or silencing of p38γ inhibits proliferation and induces CTCL cell death. The NF-κB
pathway is constitutively active in CTCL, provides a complementary T cell signaling pathway to p38γ, and can
be inhibited by histone deacetylase inhibitors (HDACi). HDACi, which are currently the most effective clinically
approved cytotoxic compounds against CTCL, demonstrate synergistic killing when combined with p38γ
Inhibition. Our objective is to understand and exploit the p38γ pathway in CTCL, using a combination of
molecular, chemical, and genetic approaches. Our first Aim is to determine the mechanisms by which p38γ
inhibition induces cell death in CTCL. We will define the kinase cascade involved in p38γ inhibition-induced
CTCL cell killing and identify phosphorylation targets of p38γ signaling; use a synthetic lethal RNAi screen to
identify signaling components that cause cell death upon depletion in the presence of p38γ inhibition; and
determine the extent to which combined inhibition of p38γ and complementary pathways, including HDACs,
induce synergistic therapeutic effects. We will validate identified proteins for the ability to affect downstream
signaling and cellular responses in vitro and in vivo, using CTCL cell line xenograft and patient-derived xenograft
(PDX) models. Our second Aim is to develop novel p38γ inhibitors for potential therapeutic application. Using
high throughput screening and molecular modeling, we identified the multi-kinase inhibitor F7 (also known as
PIK75), and showed it is an ATP-competitive p38γ inhibitor with nanomolar cytotoxic efficacy against CTCL cells.
To develop a more selective p38γ inhibitor, we will combine ligand- and structure-based computational methods
with organic synthesis; using F7 as a scaffold molecule, we will identify F7 analogs and derivatize F7 to have
higher a binding affinity for p38γ than other kinases. In addition, we will use CRISPR-based screening to identify
novel functional domains and non-conserved sites for developing allosteric next-generation therapeutics. We will
synthesize the various analogs and validate hits for CTCL cytotoxicity and p38γ-specific kinase inhibition in vitro
and in vivo, using CTCL xenograft and PDX models. We expect that successful completion of this proposal will
yield mechanistic information about the unique biological and clinical relevance of p38γ signaling and
complementary pathways in CTCL. Importantly, validation of a specific p38γ inhibitor with efficacy in CTCL
animal models will have immediate relevance for CTCL therapy.
皮肤T细胞淋巴瘤(CTCL)是一种毁容,无法治愈的癌症。对于晚期疾病患者,
目前的治疗是不充分的,结果是差的。对CTCL分子的不完全理解
监管机构限制了有效靶向治疗的发展。一个候选调节因子是p38γ,
其表达在CTCL细胞系和患者样品中选择性增加,但在健康T细胞中不增加。我们
证明p38γ的抑制或沉默抑制增殖并诱导CTCL细胞死亡。NF-κB
p38 γ通路在CTCL中是组成性活性的,为p38γ提供了互补的T细胞信号传导通路,并且可以
被组蛋白去乙酰化酶抑制剂(HDACi)抑制。HDACi是目前临床上最有效的
已批准的针对CTCL的细胞毒性化合物,当与p38γ
抑制作用我们的目的是了解和利用CTCL中的p38γ通路,
分子、化学和遗传方法。我们的第一个目标是确定p38γ
抑制诱导CTCL中的细胞死亡。我们将定义参与p38γ抑制诱导的
CTCL细胞杀伤和鉴定p38γ信号传导的磷酸化靶点;使用合成的致死RNAi筛选,
鉴定在p38γ抑制存在下耗尽时引起细胞死亡的信号传导组分;和
确定p38γ和互补途径(包括HDAC)的联合抑制程度,
诱导协同治疗作用。我们将验证鉴定的蛋白质影响下游的能力,
使用CTCL细胞系异种移植物和患者来源的异种移植物的体外和体内信号传导和细胞应答
(PDX)模型我们的第二个目标是开发具有潜在治疗应用的新型p38γ抑制剂。使用
通过高通量筛选和分子建模,我们鉴定了多激酶抑制剂F7(也称为
PIK 75),并显示其是ATP竞争性p38γ抑制剂,具有针对CTCL细胞的纳摩尔细胞毒性功效。
为了开发更有选择性的p38γ抑制剂,我们将结合联合收割机和基于配体和结构的计算方法
使用F7作为支架分子,我们将鉴定F7类似物并将F7衍生为具有
对p38γ的结合亲和力高于其他激酶。此外,我们将使用基于CRISPR的筛选来识别
用于开发下一代变构治疗剂的新功能结构域和非保守位点。我们将
合成各种类似物,并在体外验证CTCL细胞毒性和p38γ特异性激酶抑制的命中
和体内,使用CTCL异种移植物和PDX模型。我们希望,成功完成这项建议将
产生关于p38γ信号传导的独特生物学和临床相关性的机制信息,
CTCL中的互补途径。重要的是,在CTCL中有效的特异性p38γ抑制剂的验证
动物模型将与CTCL治疗直接相关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN Terry ROSEN其他文献
STEVEN Terry ROSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN Terry ROSEN', 18)}}的其他基金
Novel targeted therapies for HPV-associated Non-AIDS-defining cancers (Biospecimens/Biocohort)
针对 HPV 相关非艾滋病定义癌症的新型靶向疗法(生物样本/生物队列)
- 批准号:
10620083 - 财政年份:2022
- 资助金额:
$ 67.8万 - 项目类别:
Genomic and Microenvironment Analysis of HIV-Associated Diffuse Large B-cell Lymphoma (Immuno/Microenvironment)
HIV 相关弥漫性大 B 细胞淋巴瘤的基因组和微环境分析(免疫/微环境)
- 批准号:
10620074 - 财政年份:2022
- 资助金额:
$ 67.8万 - 项目类别:
Caribbean Investigation of Cancer Stigma and its effect on Cervical Cancer Screening and HPV Vaccination
加勒比癌症耻辱调查及其对宫颈癌筛查和 HPV 疫苗接种的影响
- 批准号:
10406126 - 财政年份:2021
- 资助金额:
$ 67.8万 - 项目类别:
Creating an Efficient Clinical Trial Build System Via the Clinical Trials Rapid Activation Consortium (CTRAC)
通过临床试验快速激活联盟 (CTRAC) 创建高效的临床试验构建系统
- 批准号:
10227589 - 财政年份:2020
- 资助金额:
$ 67.8万 - 项目类别:
Targeting p38 gamma signaling to advance Cutaneous T Cell Lymphoma Therapy
靶向 p38 γ 信号传导以推进皮肤 T 细胞淋巴瘤治疗
- 批准号:
10525229 - 财政年份:2018
- 资助金额:
$ 67.8万 - 项目类别:
Targeting p38 gamma signaling to advance Cutaneous T Cell Lymphoma Therapy
靶向 p38 γ 信号传导以推进皮肤 T 细胞淋巴瘤治疗
- 批准号:
10057371 - 财政年份:2018
- 资助金额:
$ 67.8万 - 项目类别:
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
治疗急性髓系白血病的新型 RNA 导向疗法
- 批准号:
9243226 - 财政年份:2016
- 资助金额:
$ 67.8万 - 项目类别:
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
治疗急性髓系白血病的新型 RNA 导向疗法
- 批准号:
9107212 - 财政年份:2016
- 资助金额:
$ 67.8万 - 项目类别:
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
治疗急性髓系白血病的新型 RNA 导向疗法
- 批准号:
9900748 - 财政年份:2016
- 资助金额:
$ 67.8万 - 项目类别:
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
治疗急性髓系白血病的新型 RNA 导向疗法
- 批准号:
9458707 - 财政年份:2016
- 资助金额:
$ 67.8万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 67.8万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 67.8万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 67.8万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 67.8万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 67.8万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 67.8万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 67.8万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 67.8万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 67.8万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 67.8万 - 项目类别:
Continuing Grant